PSMA6 and benign prostatic hyperplasia: The adjusted HR for treatment with alpha-1 blockers was 1.581 (95% CI: 1.16-1.915, <i>p</i> < 0.001), and increased risk with adjusted HR for treatment with high doses of 5-alpha reductase inhibitors over a long period of time are also at risk of recurrent IS.<h4>Conclusions</h4>These findings highlight the association between BPH incidence and the risk of recurrent IS.